The Series B financing round was led by Chinese venture capital firm Qiming Venture Partners and included participation from Sequoia Capital China and Genesis Capital, China Money Network reported. The investment follows a $7 million Series A round in January led by Sequoia Capital China and a $2 million angel round in 2016 from Innoangel Fund and Powercloud Venture Capital.
Infervision plans to use the new funds to support the commercialization and clinical trial of its products, as well as expand its business into overseas markets, according to the article. To date, more than 10 hospitals have implemented the company's AI software.
Copyright © 2017 AuntMinnie.com